Business Description
NRX Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US6294441000
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -3.49 | |||||
Debt-to-Equity | -0.42 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36 | |||||
3-Year EPS without NRI Growth Rate | 37.6 | |||||
3-Year FCF Growth Rate | -62.8 | |||||
3-Year Book Growth Rate | 46.7 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 38.4 | |||||
14-Day RSI | 46.45 | |||||
6-1 Month Momentum % | -7.43 | |||||
12-1 Month Momentum % | 109.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.21 | |||||
Quick Ratio | 0.21 | |||||
Cash Ratio | 0.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.9 | |||||
Shareholder Yield % | -13.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -251.79 | |||||
ROIC % | -221.48 | |||||
3-Year ROIIC % | 251.9 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.96 | |||||
EV-to-Forward-EBIT | -1.78 | |||||
EV-to-EBITDA | -0.96 | |||||
EV-to-Forward-Revenue | 5.41 | |||||
EV-to-FCF | -1.66 | |||||
Earnings Yield (Greenblatt) % | -103.82 | |||||
FCF Yield % | -78.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
NRX Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -8.619 | ||
Beta | 2.03 | ||
Volatility % | 97.87 | ||
14-Day RSI | 46.45 | ||
14-Day ATR (€) | 0.000024 | ||
20-Day SMA (€) | 4.86 | ||
12-1 Month Momentum % | 109.48 | ||
52-Week Range (€) | 2.08 - 6.7 | ||
Shares Outstanding (Mil) | 10.75 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NRX Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NRX Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
NRX Pharmaceuticals Inc Frequently Asked Questions
What is NRX Pharmaceuticals Inc(FRA:B1Q)'s stock price today?
When is next earnings date of NRX Pharmaceuticals Inc(FRA:B1Q)?
Does NRX Pharmaceuticals Inc(FRA:B1Q) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |